Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.51 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.51 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.49 |
| ▸ | CHRNG | P07510 | 1/20 | 0.49 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30147734 | 1.00 | CES2 (0.59) | CES2CES1HDAC6HDAC8HDAC2 | |
| SCHEMBL8515075 | 0.84 | ESRRG (0.50) | HDAC6HDAC8HDAC2HDAC1THRB | |
| SCHEMBL30102019 | 0.84 | HDAC6 (0.53) | HDAC6HDAC8HDAC2HDAC1KCNQ3 | |
| SCHEMBL30147494 | 0.84 | HDAC6 (0.73) | HDAC6HDAC8HDAC2HDAC1KCNQ3 | |
| SCHEMBL1441177 | 0.84 | HDAC6 (0.73) | HDAC6HDAC8HDAC2HDAC1KCNQ3 | |
| SCHEMBL1507188 | 0.84 | HDAC6 (0.53) | HDAC6HDAC8HDAC2HDAC1KCNQ3 | |
| SCHEMBL29306646 | 0.84 | GAA (0.58) | HDAC6HDAC8HDAC2HDAC1THRB | |
| SCHEMBL5019978 | 0.82 | HDAC6 (0.47) | HDAC6HDAC8HDAC2HDAC1THRB | |
| SCHEMBL3819667 | 0.82 | HDAC6 (0.52) | HDAC6HDAC8HDAC2HDAC1THRB | |
| SCHEMBL355600 | 0.82 | HDAC6 (0.71) | HDAC6HDAC8HDAC2HDAC1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| WO-2019204180-A1 | NOVEL [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019148132-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| CN-108752155-A | A method of synthesis N- aryl methanamide compounds | 西京学院 | 2018-11-06 | — | — | CN | disclosed |
| US-9187497-B2 | Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9187497-B2 | Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9187497-B2 | Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| CN-102341394-B | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL | 2015-04-15 | — | — | CN | disclosed |
| US-8980902-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20100234378-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085570-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085570-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | COLEY PHARMACEUTIAL GROUP, INC. (NY) | 2009-04-16 | — | — | US | disclosed |
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | COLEY PHARMACEUTIAL GROUP, INC. (NY) | 2009-04-16 | — | — | US | disclosed |
| WO-2008016811-A2 | AMINOPIPERIDINES AND REALTED COMPOUNDS | NEUROGEN CORPORATION (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | CES2 2086/4885CES1 1899/4885HDAC6 738/4885 |
| US-20100234378-A1 | ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS | MMP3, MMP11, MMP13 | CES2 463/4885CES1 229/4885HDAC6 82/4885 |
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | IL2, EIF2AK2, IFNG | CES2 2151/4885CES1 2194/4885HDAC6 258/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | CES2 4573/4885CES1 2298/4885HDAC6 161/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CES2 1051/4885CES1 1230/4885HDAC6 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.